Julie A Johnson

Dr. Johnson’s research programs focus on inter-patient variability in drug response, particularly cardiovascular drug pharmacogenomics, and translation of pharmacogenomics into clinical practice. Her discovery research centers around the pharmacogenomics of antihypertensive drugs, and drugs used to prevent clot formation. She leads a research team funded by the NIH Pharmacogenomics Research Network, with a project focused on pharmacogenomics of antihypertensive drugs, leads the International Warfarin Pharmacogenetics Consortium, and leads one of the funded groups in the NIH’s genomic medicine implementation network, called IGNITE, for which she was also inaugural chair of its steering committee. She is a member of the National Academy of Medicine.